@article{b142e074a9f346e6b4383df0eaea55e5,
title = "How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy",
abstract = "Chimeric antigen receptor (CAR) T cells have transformed the care for patients with hematologic malignancies. Patients treated with CAR T cells may experience cardiovascular and pulmonary complications, which primarily occur in the setting of cytokine release syndrome. In addition, many patients considered for CAR T-cell therapy have preexisting cardiac and pulmonary comorbidities. Among patients with good functional status, these conditions should not prevent patients from being offered these lifesaving therapies. In this article, we use a case-based approach to discuss how we evaluate and optimize conditions for patients with cardiac and pulmonary risk factors before CAR T-cell therapy and manage cardiac and pulmonary complications that may arise with treatment.",
author = "Cristina Gutierrez and Neilan, {Tomas G.} and Grover, {Natalie S.}",
note = "Funding Information: T.G.N. is supported by a gift from A. Curt Greer and Pamela Kohlberg and from Christina and Paul Kazilionis, the Michael and Kathryn Park Endowed Chair in Cardiology, and a Hassenfeld Scholar Award and is also supported by grants from the National Institutes of Health / National Heart, Lung, and Blood Institute ( R01HL130539 , R01HL137562 , and K24HL150238 ). N.S.G. is supported by the Lymphoma Research Foundation Career Development Award. Funding Information: The authors thank Fabiana Perna and Nirali Shah for their input and review of the manuscript. The authors acknowledge the efforts of the American Society of Hematology's subcommittee on Emerging Gene and Cell Therapies for their support in prioritizing the need to discuss emergent CAR T-cell toxicities. T.G.N. is supported by a gift from A. Curt Greer and Pamela Kohlberg and from Christina and Paul Kazilionis, the Michael and Kathryn Park Endowed Chair in Cardiology, and a Hassenfeld Scholar Award and is also supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute (R01HL130539, R01HL137562, and K24HL150238). N.S.G. is supported by the Lymphoma Research Foundation Career Development Award. Contribution: C.G. T.G.N. and N.S.G. wrote and edited the manuscript. Publisher Copyright: {\textcopyright} 2023 The American Society of Hematology",
year = "2023",
month = may,
day = "18",
doi = "10.1182/blood.2022017579",
language = "English (US)",
volume = "141",
pages = "2452--2459",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",
}